Blog
Is Intel Surrendering the Desktop Market to AMD?
Over the past year, Intel's (NASDAQ: INTC) ongoing shortage of 14nm chips allowed AMD (NASDAQ: AMD) to gain significant ground in the PC and data center markets. Intel is struggling to resolve those
3 Things You'll Want to Know About Abbott Labs' Q3 Results
Good but not great: That's pretty much been how 2019 has gone so far for Abbott Labs (NYSE:ABT) when it comes to stock performance. Shares of the medical-device maker are up more than 11% year to
Disney World's Top Rival Is Wild to Be Bourne
Disney (NYSE: DIS) has been beefing up its Florida theme parks, ahead of the resort turning 50 in 2021. Sensing that an arms race is afoot, Comcast (NASDAQ: CMCSA) is also updating the attractions
ASML Grows Sales Despite Memory Weakness
Dutch semiconductor equipment supplier ASML Holding (NASDAQ: ASML) reported mixed third-quarter results on Wednesday morning. While revenue was up, driven by system sales to logic customers, a weak
Better Buy: Cisco Systems vs. Microsoft
Cisco (NASDAQ: CSCO) and Microsoft (NASDAQ: MSFT) are generally considered solid long-term investments for conservative investors. Both tech giants have wide moats -- Cisco is the world's top maker
Better Buy: Walmart vs. Amazon
We all know that Amazon is the 800-pound gorilla in online retail. But were you aware that Walmart is making serious strides of its own toward becoming an e-commerce force? It started with the $3
Amazon's Starting to Pull Away From Competitors in Search Advertising
When it comes to the search advertising market in the United States, there's Google and then there's everyone else. But Amazon (NASDAQ: AMZN) is making the case that it deserves some recognition
Why Aurinia Pharmaceuticals Is Soaring Today
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH), a clinical-stage biopharmaceutical company focused on rare diseases, were up 10% as of 11:05 a.m. EDT on Tuesday after management issued a press
Better Tech Stock Buy: Facebook vs. Google Parent Alphabet
Big technology companies seem to be steadily taking over the world, so it's natural that many investors want to invest in one or more of them.
We're going to explore which two of the "big tech"
Stock Market News: MGM Sells Vegas Icons; United Flies Higher
Major benchmarks were mixed on Wednesday as investors paused following sizable gains from Tuesday's session. Market participants kept a close eye on Hong Kong, where pro-democracy protestors have
Alphabet Steps Up Its Hardware Game Again
For the most part, Alphabet's (NASDAQ: GOOGL) (NASDAQ: GOOG) business is driven by online advertising. The company generates revenue from sales of advertisement placements on its own websites
Canopy Growth Strikes 2 Deals
Canopy Growth (NYSE: CGC), which is considered a leading marijuana stock, is reconfiguring itself with a pair of deals announced on Monday.
The first is the company's closing of its acquisition of
Do Consumers Really Need Foldable Phones? Samsung and Microsoft Hope So
First it was Samsung (OTC: SSNLF) failed effort in April and retry in early September. Then Microsoft (NASDAQ: MSFT) announced one a few weeks later.
Foldable smartphones seem to be all the rage
3 Stocks With at Least a Decade of Dividend Growth Under Their Belts
The first thing most dividend investors look at in an income stock is its yield. While the payout matters, an even more important factor is dividend growth.
The data bears this out. Since 1972
Better Buy: Arista Networks vs. Juniper Networks
Roles have seemingly reversed for Arista Networks (NYSE: ANET) and Juniper Networks (NYSE: JNPR). A year ago, Wall Street had the former on a pedestal, touting its strong double-digit growth pace
Is Anyone Willing to Bail Out Chinese Electric-Car Maker NIO?
A deal to provide Chinese electric-car maker NIO (NYSE: NIO) with urgently needed cash to build a factory has fallen through because of "heavy risks," according to a new report from China's National
3 Top Tech Stocks to Buy in October
Many tech stocks are struggling under the weight of the trade war between China and Washington. The major indexes notched all-time highs in July and then backed off again in August and September
3 Numbers to Watch in Coca-Cola’s Earnings Report
Investors have been happy with Coca-Cola's (NYSE: KO) last few earnings reports for a change. The new optimism comes from accelerating sales growth driven by core innovations like Coke Zero and
Why Achillion Pharmaceuticals Stock Is Skyrocketing Today
Shares of the clinical-stage biotech Achillion Pharmaceuticals (NASDAQ: ACHN) rose by a jaw-dropping 82% on heavy volume in pre-market trading this morning.
The spark? Achillion's shares bolted
3 High-Growth Tech Stocks to Buy for 2020 and Beyond
Technology stocks always attract a large following. No matter how many tech bubbles go boom and bust, analysts and investors are always on the lookout for the next big tech superstar (and the
Bank of America: The Winner of Third-Quarter Bank Earnings
Bank of America (NYSE: BAC) was the fourth out of the "big four" U.S. banks to report earnings, and it appears the best has been saved for last. Not only did the bank beat earnings and revenue
United Airlines Reports Another Excellent Quarter -- but Momentum Is Slowing
United Airlines (NASDAQ: UAL) posted stellar earnings growth in the first half of 2019, as solid demand and lower fuel prices allowed the airline to expand its adjusted pre-tax margin to 8.6% from
Is Wall Street Too Bearish on Grubhub?
Grubhub (NYSE: GRUB) lost nearly 30% of its value this year as concerns about the meal delivery company's slowing growth and rising expenses piled up. Yet most analysts still remain either bullish
New CEO Sends Bed Bath & Beyond Shares Up 20%, but Is He Really the Answer?
If the stock's 20% jump following last Wednesday's announcement is any indication, investors are optimistic that the new Bed Bath & Beyond (NASDAQ: BBBY) CEO is the right person to rekindle growth
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
Nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease, is widely expected to be the next big thing in biopharma. Thanks to the out-of-control obesity pandemic and


